Text Size

Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model

Jauhonen H.-M., Laihia J., Oksala O., Viiri J., Sironen R., Alajuuma P., Kaarniranta K., Leino L.


  • 2017
  • Graefe's Archive for Clinical and Experimental Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Preclinical development

  • Affiliations

    Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; Institute of Clinical Medicine, Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Finland, P.O. Box 1627, Kuopio, FIN-70211, Finland; BioCis Pharma Ltd, Turku, Finland; Santen Oy, Tampere, Finland; Institute of Clinical Medicine, Department of Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland; Department of Pathology, Kuopio University Hospital, Kuopio, Finland

Related Publications

Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits

Mochizuki T.; Hata T.; Mori N.; Yamazaki T.; Noto T.; Mano H.


Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022